Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - somatropin, quantity: 10 mg - injection, solution - excipient ingredients: phenol; poloxamer; sodium hydroxide; phosphoric acid; monobasic sodium phosphate dihydrate; dibasic sodium phosphate heptahydrate; water for injections; glycine - omnitrope is intended for the long term treatment of children (above three years of age) with, growth disturbance due to insufficient secretion of pituatary growth hormone, growth disturbance associated with gonadal dysgenesis (turner syndrome), growth disturbance associated with chronic renal insufficiency.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - somatropin, quantity: 3.3 mg/ml - injection - excipient ingredients: poloxamer; dibasic sodium phosphate heptahydrate; benzyl alcohol; sodium hydroxide; monobasic sodium phosphate; mannitol; water for injections; phosphoric acid - omnitrope is intended for long term treatment of children (above three years of age with growth disturbance due to insufficient secretion of pituitary growth hormone; growth disturbance associated with gonadal dysgenesis (turner's syndrome); & growth disturbance associated with chronic renal insufficiency.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - somatropin, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; phenol; phosphoric acid; water for injections; sodium chloride; monobasic sodium phosphate dihydrate; dibasic sodium phosphate heptahydrate; poloxamer - omnitrope is intended for the long term treatment of children (above three years of age) with:,- growth disturbance due to insufficient secretion of pituitary growth hormone,- growth disturbance associated with gonadal dysgenesis (turner syndrome),- growth disturbance associated with chronic renal insufficiency.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - somatropin, quantity: 10 mg - injection, solution - excipient ingredients: phenol; poloxamer; sodium hydroxide; phosphoric acid; monobasic sodium phosphate dihydrate; dibasic sodium phosphate heptahydrate; water for injections; glycine - omnitrope is intended for the long term treatment of children (above three years of age) with, growth disturbance due to insufficient secretion of pituatary growth hormone, growth disturbance associated with gonadal dysgenesis (turner syndrome), growth disturbance associated with chronic renal insufficiency.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - iohexol, quantity: 518 mg/ml (equivalent: iodine, qty 240 mg/ml) - injection, solution - excipient ingredients: trometamol; sodium calcium edetate; hydrochloric acid; water for injections - indications as at 12 november 2003: intravascular: omnipaque is indicated in adults for angiography, excretory urography and contrast enhancement in computerised tomography. in children, omnipaque is indicated for angiography and urography. oral/body cavities: omnipaque is indicated in adults for arthrography, endoscopic retrograde pancreatography (erp), endoscopic retrograde cholangiopancreatography (ercp), herniography, hysterosalpingography and in adults, children and premature babies for studies of the gastrointestinal tract.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - iohexol, quantity: 647 mg/ml (equivalent: iodine, qty 300 mg/l) - injection, solution - excipient ingredients: trometamol; sodium calcium edetate; hydrochloric acid; water for injections - indications as at 12 november 2003: intravascular: omnipaque is indicated in adults for angiography, excretory urography and contrast enhancement in computerised tomography. in children, omnipaque is indicated for angiography and urography. oral/body cavities: omnipaque is indicated in adults for arthrography, endoscopic retrograde pancreatography (erp), endoscopic retrograde cholangiopancreatography (ercp), herniography, hysterosalpingography and in adults, children and premature babies for studies of the gastrointestinal tract.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - iohexol, quantity: 388 mg/ml (equivalent: iodine, qty 180 mg/ml) - injection, solution - excipient ingredients: trometamol; sodium calcium edetate; hydrochloric acid; water for injections - intrathecal: omnipaque is indicated for lumbar, thoracic, cervical and total columnar myelography and in computerised tomography of the cns in adults and children. indications as at 12 november 2003: intravascular: omnipaque is indicated in adults for angiography, excretory urography and contrast enhancement in computerised tomography. in children, omnipaque is indicated for angiography and urography. oral/body cavities: omnipaque is indicated in adults for arthrography, endoscopic retrograde pancreatography (erp), endoscopic retrograde cholangiopancreatography (ercp), herniography, hysterosalpingography and in adults, children and premature babies for studies of the gastrointestinal tract.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - iohexol, quantity: 755 mg/ml (equivalent: iodine, qty 350 mg/ml) - injection, solution - excipient ingredients: trometamol; sodium calcium edetate; hydrochloric acid; water for injections - indications as at 12 november 2003: intravascular: omnipaque is indicated in adults for angiography, excretory urography and contrast enhancement in computerised tomography. in children, omnipaque is indicated for angiography and urography. oral/body cavities: omnipaque is indicated in adults for arthrography, endoscopic retrograde pancreatography (erp), endoscopic retrograde cholangiopancreatography (ercp), herniography, hysterosalpingography and in adults, children and premature babies for studies of the gastrointestinal tract.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - iohexol, quantity: 647 mg/ml (equivalent: iodine, qty 300 mg/ml) - injection, solution - excipient ingredients: trometamol; sodium calcium edetate; hydrochloric acid; water for injections - indications as at 12 november 2003: intravascular: omnipaque is indicated in adults for angiography, excretory urography and contrast enhancement in computerised tomography. in children, omnipaque is indicated for angiography and urography. oral/body cavities: omnipaque is indicated in adults for arthrography, endoscopic retrograde pancreatography (erp), endoscopic retrograde cholangiopancreatography (ercp), herniography, hysterosalpingography and in adults, children and premature babies for studies of the gastrointestinal tract.

Australia - English - Department of Health (Therapeutic Goods Administration)

ge healthcare australia pty ltd - iohexol, quantity: 518 mg/ml (equivalent: iodine, qty 240 mg/ml) - injection, solution - excipient ingredients: trometamol; sodium calcium edetate; hydrochloric acid; water for injections - indications as at 12 november 2003: intravascular: omnipaque is indicated in adults for angiography, excretory urography and contrast enhancement in computerised tomography. in children, omnipaque is indicated for angiography and urography. oral/body cavities: omnipaque is indicated in adults for arthrography, endoscopic retrograde pancreatography (erp), endoscopic retrograde cholangiopancreatography (ercp), herniography, hysterosalpingography and in adults, children and premature babies for studies of the gastrointestinal tract.